Stream and listen to our webinar on smart lead optimization!
Luca Raveglia, Head of Medicinal Chemistry, discusses novel approaches to the selection of higher quality clinical candidates.
Stream the webinar today!
Identifying new drugs is getting more and more challenging: the clinical success rate has declined significantly in the last decade whilst development costs increased. Overall, the success rate from Preclinical to NDA approval is lower than 5%, meaning that most of R&D expenditure is associated with failures.
There are a number of strategies that Pharmaceutical companies are applying to revert this trend, one being a more stringent control of physicochemical properties during Lead Optimization, which proved to be beneficial in decreasing clinical failures due to safety reasons. Generally, it is clear that the quality of the discovery candidate will highly impact on Development attrition rate, thus making candidate selection the most important decision in Drug Discovery and Development.
Stream our webinar today where we discuss
- Fit for Purpose Lead Optimization
- Targeting the Right Chemical Space
- Drug Efficiency in Lead Optimization
- Translational Approaches and Biomarkers